

LIGAND PHARMACEUTICALS INC
Form SC 13G/A
April 10, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2) *

Ligand Pharmaceuticals Incorporated

(Name of Issuer)

Class B Common Stock

(Title of Class of Securities)

53220K-20-7

(CUSIP Number)

March 31, 2003

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

/X/ Rule 13d-1(b)
/ / Rule 13d-1(c)
/ / Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1
of 7 Pages

SCHEDULE 13G

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

(1) NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Salomon Smith Barney Holdings Inc.

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) / /

(b) / /

(3) SEC USE ONLY

(4) CITIZENSHIP OR PLACE OF ORGANIZATION New York

NUMBER OF (5) SOLE VOTING POWER 0
SHARES

BENEFICIALLY (6) SHARED VOTING POWER 159,552*

OWNED BY EACH (7) SOLE DISPOSITIVE POWER 0

REPORTING PERSON (8) SHARED DISPOSITIVE POWER 159,552*

WITH:

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 159,552*

(10) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) / /

(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.2%*

(12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

* Assumes conversion/exercise of certain securities held.

SCHEDULE 13G

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

CUSIP NO. 53220K-20-7

Page 3 of 7 Pages

 (1) NAMES OF REPORTING PERSONS
 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Citigroup Inc.

 (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) / /
 (b) / /

 (3) SEC USE ONLY

 (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

 NUMBER OF (5) SOLE VOTING POWER 0

SHARES

BENEFICIALLY (6) SHARED VOTING POWER 483,533*
**

OWNED BY

EACH (7) SOLE DISPOSITIVE POWER 0

REPORTING

PERSON (8) SHARED DISPOSITIVE POWER 483,533*
**

WITH:

 (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 483,533*
**

 (10) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) / /

 (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.7%*
**

 (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC

 * Assumes conversion/exercise of certain securities held.

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

** Includes shares held by the other reporting person.

Item 1(a). Name of Issuer:

Ligand Pharmaceuticals, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

10275 Science Center Drive
San Diego, CA 92121

Item 2(a). Name of Person Filing:

Salomon Smith Barney Holdings Inc. ("SSB Holdings")
Citigroup Inc. ("Citigroup")

Item 2(b). Address or Principal Office or, if none, Residence:

The address of the principal office of SSB Holdings is:

388 Greenwich Street
New York, NY 10013

The address of the principal office of Citigroup is:

399 Park Avenue
New York, NY 10043

Item 2(c). Citizenship or Place of Organization:

SSB Holdings is a New York corporation.

Citigroup is a Delaware corporation.

Item 2(d). Title of Class of Securities:

Class B Common Stock

Item 2(e). Cusip Number:

53220K-20-7

Page 4
of 7 Pages

Item 3. If this Statement is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a(n):

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

- (e) [] Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
- (f) [] Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
- (g) [X] Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (See Exhibit 2)
- (h) [] Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) [] Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
- (j) [] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).

Item 4. Ownership. (as of March 31, 2003)

- (a) Amount beneficially owned: See item 9 of cover pages
- (b) Percent of Class: See item 11 of cover pages
- (c) Number of shares as to which the person has:
 - (i) sole power to vote or to direct the vote:
 - (ii) shared power to vote or to direct the vote:
 - (iii) sole power to dispose or to direct the disposition of:
 - (iv) shared power to dispose or to direct the disposition of:

See Items 5-8 of cover pages

Page 5
of 7 Pages

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security being Reported on by the Parent Holding Company.

See Exhibit 2 for the identity and classification of the subsidiary(s) which directly beneficially own the securities reported herein.

Item 8. Identification and Classification of Members of the Group.

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Page 6
of 7 Pages

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 9, 2003

SALOMON SMITH BARNEY HOLDINGS INC.

By: /s/ Joseph B. Wollard

Name: Joseph B. Wollard
Title: Assistant Secretary

CITIGROUP INC.

By: /s/ Serena D. Moe

Name: Serena D. Moe
Title: Assistant Secretary

Page 7
of 7 Pages

EXHIBIT INDEX TO SCHEDULE 13G

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

EXHIBIT 1

Agreement between SSB Holdings and Citigroup as to joint filing of Schedule 13G

EXHIBIT 2

Identification and Item 3 Classification of the Subsidiary(s) which acquired securities being reported by the Parent Holding Company(s).